Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PARP inhibitor

- PMLiVE

AstraZeneca sells rights to seven anaesthetics in $770m deal

Ten-year agreement with Aspen continues the streamlining of its operations

- PMLiVE

AstraZeneca to develop Lynparza companion diagnostic

Will collaborate with Foundation Medicine on test for its ovarian cancer drug

AstraZeneca AZ

AZ sells Zurampic rights to Gruenenthal for $230m

Continues to sell off unwanted assets in order to focus resources and meet $45bn sales target

- PMLiVE

GSK brings forward triple COPD therapy filing in US

Intends to file the three-drug respiratory therapy by the end of 2016

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

China drug medicine pharma prices

Prices of AZ and GSK drugs slashed in China

GSK says price reductions represent  “defining moment” in improving patient outcomes

AstraZeneca AZ global R&D corporate HQ

AZ gets orphan status for selumetinib in thyroid cancer

Drug already in phase III testing for KRAS-mutant advanced NSCLC

UK flag

UK biopharma says Brexit would be “bad for business”

Over 90 industry leaders sign letter supporting the Remain campaign

Deal Watch March 2016

AstraZeneca, Roche, Sanofi and Valeant are featured in this month’s roundup of pharma deals

AstraZeneca AZ

CHMP backs AZ’s ‘superbug’ antibiotic product

Zavicefta recommended for European approval

AstraZeneca AZ

AZ adds gout drug Zurampic to asset sale

Ironwood Pharmaceuticals buys exclusive US rights to the therapy and follow-up product

AstraZeneca AZ

AstraZeneca sets up genomics consortium for drug discovery

Will launch dedicated research centre to analyse data from clinical trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links